SGLT2 inhibitors vs placebo
4P‐MACE median · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors probably leads to lower 4P‐MACE median compared with placebo (moderate certainty).
1 finding from 1 review
- Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes 2024 · Cochrane Headline outcomes onlyRR 0.82 [0.7, 0.96]4 studies · 23539 participantsModerate